Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Epithelial Ovarian Cancer Market?

Over the years, the epithelial ovarian cancer market has experienced a swift surge. The market is projected to expand from $2.08 billion in 2024 to $2.42 billion in 2025, with a compound annual growth rate (CAGR) of 16.5%. This significant increase during the historic period is due to the burgeoning need for personalized cancer therapies, escalation in global healthcare spending, a rising preference for less invasive surgical procedures, an increased number of ovarian cancer survivors, a growing call for gene therapies, and a heightened demand for palliative care offerings.

What Growth Rate Is Forecasted for the Epithelial Ovarian Cancer Market by 2029?

Predictions indicate a swift expansion in the epithelial ovarian cancer market in the upcoming years, with an estimated value of $4.41 billion in 2029 and a compound annual growth rate (CAGR) of 16.1%. This projected growth within the forecasted period is primarily due to a rise in ovarian cancer incidents, an aging demographic, heightened awareness around ovarian cancer, an increase in cancer research funding and heightened governmental efforts in fighting cancer. Key trends anticipated to become prominent during the forecast period are the ongoing improvements in medical imaging technology, the advent of novel molecular diagnostic instruments, cross-collaboration among pharmaceutical firms, the swift embrace of Artificial Intelligence and machine learning within the realm of diagnostics, and the broadening application of robotic surgeries.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp

Which Key Companies Are Shaping the Future of the Epithelial Ovarian Cancer Market?

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., Vivesto AB

Which Factors Are Driving Demand in the Epithelial Ovarian Cancer Industry?

The anticipated rise in ovarian cancer cases is predicted to fuel the expansion of the epithelial ovarian cancer market. Ovarian cancer, which mainly affects the epithelial cells coating the ovarian surface, initiates in the ovaries. Factors like an aging demographic, enhanced awareness, improved detection rates, as well as genetic and lifestyle influences contribute mainly towards the increasing prevalence of ovarian cancer. To tackle the most common and aggressive variant of ovarian cancer, treatment for epithelial ovarian cancer is necessary. The aim is to target the cancerous cells to raise survival rates and patient outcomes. For example, in February 2024, the World Ovarian Cancer Coalition, a Canada-based non-profit organization, predicted that by 2050, the count of females diagnosed with ovarian cancer worldwide would rise by over 55%, obtaining a total of 503,448. The yearly ovarian cancer fatality rate is also forecast to escalate to 350,956, marking almost a 70% surge from 2022. Therefore, the escalating prevalence of ovarian cancer will be a significant driving force for the epithelial ovarian cancer market in the future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20778&type=smp

How Is the Epithelial Ovarian Cancer Market Segmented by Several Divisions?

The epithelial ovarian cancer market covered in this report is segmented –

1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery

2) By Drug Class: Platinum-based Chemotherapy Drugs, Poly(ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents

3) By Stage Of Cancer: Early Stage, Advanced Stage

4) By Diagnosis Method: Imaging, Biopsy, Blood Tests

5) By End User: Hospitals, Clinics, Diagnostic Laboratories

Subsegments:

1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy

2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors, Other Targeted Agents

3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy

4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins

5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy, Other Surgical Procedures

What are the Emerging Market Trends Driving the Growth of the Epithelial Ovarian Cancer Industry?

Leading corporations in the epithelial ovarian cancer market are directing their efforts towards the creation of innovative treatment solutions, including FRa-directed antibody-drug conjugates (ADCs). These innovative solutions are designed to target the folate receptor-alpha found in abundance on cancer cells and deliver lethal cytotoxic agents while keeping damage to healthy tissue to a minimum. An FRa-directed ADC is a specialized cancer treatment that pairs an antibody specific to the folate receptor-alpha (FRa) with a cytotoxic medicine, facilitating targeted drug delivery to cancer cells expressing this receptor. For example, in November 2024, the US-based biopharmaceutical firm AbbVie Inc. gained approval from the European Commission for ELAHERE (mirvetuximab soravtansine). This is a targeted therapy for adult patients suffering from folate receptor-alpha (FRa) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE presents a new and effective treatment path for patients who have undergone up to three previous systemic regimens. The treatment targets a biomarker present in approximately a third of ovarian cancer patients, thus improving chances of survival and enhancing quality of life. The approval also includes a companion diagnostic to identify eligible patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

Which Regions Are Driving Growth in the Epithelial Ovarian Cancer Market?

North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20778

This Report Delivers Insight On:

1. How big is the epithelial ovarian cancer market, and how is it changing globally?

2. Who are the major companies in the epithelial ovarian cancer market, and how are they performing?

3. What are the key opportunities and risks in the epithelial ovarian cancer market right now?

4. Which products or customer segments are growing the most in the epithelial ovarian cancer market?

5. What factors are helping or slowing down the growth of the epithelial ovarian cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model